Qube Research & Technologies (QRT)
REGN icon

Qube Research & Technologies (QRT)’s Regeneron Pharmaceuticals REGN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.3M Sell
5,300
-3,100
-37% -$2.11M ﹤0.01% 1845
2026
Q1 		$6.49M Sell
8,400
-20,600
-71% -$15.8M 0.01% 1530
2025
Q4 		$22.4M Sell
29,000
-14,900
-34% -$10.1M 0.02% 848
2025
Q3 		$24.7M Buy
43,900
+4,200
+11% +$2.37M 0.03% 796
2025
Q2 		$20.8M Buy
39,700
+31,800
+403% +$17.7M 0.02% 855
2025
Q1 		$5.01M Buy
7,900
+5,400
+216% +$3.71M 0.01% 1523
2024
Q4 		$1.78M Buy
+2,500
New +$2.1M ﹤0.01% 1927
2024
Q2 		– Sell
-2,600
Closed -$2.5M – 4564
2024
Q1 		$2.5M Buy
+2,600
New +$2.47M ﹤0.01% 1626

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Qube Research & Technologies (QRT)'s REGN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Regeneron Pharmaceuticals (REGN) stake by 166% in Q2 2026, buying an estimated $94.1M and bringing the position to 221,607 shares worth $138M. The position accounts for 0.13% of the portfolio, ranked #196.

Qube Research & Technologies (QRT) first reported a position in REGN in Q3 2018 and has held it in 23 quarters since. The position peaked at $446M in Q1 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Qube Research & Technologies (QRT) held 221,607 shares of Regeneron Pharmaceuticals worth $138M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 138,249 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $94.1M.
  • Regeneron Pharmaceuticals made up 0.13% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #196 holding.
  • Qube Research & Technologies (QRT) first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
  • Qube Research & Technologies (QRT)'s Regeneron Pharmaceuticals position peaked at $446M in Q1 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.